Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP244609.RAeCnbxnQJSyHgWeRwAuONmgmTZndsE7r5x2hIK9rIDcM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP244609.RAeCnbxnQJSyHgWeRwAuONmgmTZndsE7r5x2hIK9rIDcM130_assertion type Assertion NP244609.RAeCnbxnQJSyHgWeRwAuONmgmTZndsE7r5x2hIK9rIDcM130_head.
- NP244609.RAeCnbxnQJSyHgWeRwAuONmgmTZndsE7r5x2hIK9rIDcM130_assertion description "[Most importantly, the translation of the described results to human primary samples demonstrated that patients with prostate or breast tumors with low levels of KLF2 and high expression of EZH2 had a shorter overall survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP244609.RAeCnbxnQJSyHgWeRwAuONmgmTZndsE7r5x2hIK9rIDcM130_provenance.
- NP244609.RAeCnbxnQJSyHgWeRwAuONmgmTZndsE7r5x2hIK9rIDcM130_assertion evidence source_evidence_literature NP244609.RAeCnbxnQJSyHgWeRwAuONmgmTZndsE7r5x2hIK9rIDcM130_provenance.
- NP244609.RAeCnbxnQJSyHgWeRwAuONmgmTZndsE7r5x2hIK9rIDcM130_assertion SIO_000772 21892211 NP244609.RAeCnbxnQJSyHgWeRwAuONmgmTZndsE7r5x2hIK9rIDcM130_provenance.
- NP244609.RAeCnbxnQJSyHgWeRwAuONmgmTZndsE7r5x2hIK9rIDcM130_assertion wasDerivedFrom befree-20140225 NP244609.RAeCnbxnQJSyHgWeRwAuONmgmTZndsE7r5x2hIK9rIDcM130_provenance.
- NP244609.RAeCnbxnQJSyHgWeRwAuONmgmTZndsE7r5x2hIK9rIDcM130_assertion wasGeneratedBy ECO_0000203 NP244609.RAeCnbxnQJSyHgWeRwAuONmgmTZndsE7r5x2hIK9rIDcM130_provenance.